The management of high-risk prostate cancer following radical prostatectomy remains a treatment dilemma. Multimodality approaches incorporating surgery, radiation therapy and systemic agents offer the hope of improved cure rates; however, most randomized studies to date are either immature or negative. The systemic treatment options best studied is androgen deprivation, which has been shown to demonstrate a survival advantage in patients with lymph node-positive disease. Systemic chemotherapy has demonstrated a modest survival advantage in androgen-independent disease. Current studies are exploring its role in the adjuvant and neo-adjuvant setting. Lastly, recent randomized trials have demonstrated a biochemical advantage to adjuvant radiation therapy, but it remains to be seen if this will translate to an improvement is survival end points or if salvage radiation therapy would be just as effective. In this update article, we review the use of external beam radiation therapy and systemic agents in combination with surgery for high-risk prostate cancer patients.
Introduction
Prostate cancer is a large and increasing medical problem in most developed countries. In the United States alone, it is estimated that in 2006 approximately 234 460 new cases will be diagnosed and 27 350 men will die of the disease. 1 This makes prostate carcinoma the most common malignancy and second most common cause of cancer death in men. Recently, there has been a subtle but clear decrease in mortality. 1, 2 This drop in mortality has been, in large part, attributed to prostate specific antigen (PSA)-based screening and aggressive local treatment; not to improved treatment of systemic disease. 3 Unfortunately, despite aggressive PSA-based screening, many patients still present with aggressive, potentially lethal disease and/or progress despite aggressive local therapy. About 30-40% of these men will show evidence of rising serum PSA levels as evidence of recurrent disease within 10 years of follow-up. 4, 5 Risk of treatment failure following radical prostatectomy can be categorized based on clinical characteristics; patients with positive surgical margins, extracapsular disease, a high Gleason score, positive lymph nodes or positive seminal vesicles do poorly compared to patients with organ-confined disease, low Gleason score or negative margins. [5] [6] [7] Multiple risk classification schemes have been devised. D'Amico et al. 8 divided patients into low risk (oT2a, Gleasonp6, PSAo10 ng/ml), intermediate risk (T2b, Gleason ¼ 7, PSA 10-20 ng/ml) and high risk (T2c, Gleason scores 8-10, PSA420 ng/ml). The risk categories correlate with risk of biochemical recurrence rates following treatment. Although more complex, nomograms more accurately reflect patient's true risk than classification schemes. 9 By incorporating stage, grade and PSA, an accurate assessment of patients risk of recurrence up to 10 years following radical prostatectomy can be determined. 10 Nomograms commonly report a risk of recurrence as a percentage of patients who will have recurrence at a time point. Therefore, the designation of 'high risk' is not defined. Clinical trials often use a risk of recurrence of 40% or greater at 5 years; however, this benchmark has been arrived at largely by consensus.
The increased risk associated with adverse pathology does not simply translate to a decrease in biochemicalfree survival, but also a decrease in disease-specific and overall survival, 7 which is believed to be secondary to micrometastatic disease at the time of diagnosis. 11 As a result, further improvements in cure rates for this disease will depend on improved systemic therapy and a multimodality approach to treatment.
Radiation therapy
The use of external beam radiation therapy (EBRT), directed at the region where the prostate gland had been resected, is based on the belief that prostate cancer persists locally and it is the only form of therapy for radical prostatectomy failures that can still cure. The use of EBRT in men with an undetectable PSA and no evidence disease after radical prostatectomy is considered adjuvant. The decision to perform EBRT in the adjuvant setting is usually based on an unfavorable pathological specimen, for example, positive surgical margins, which are associated with higher rates of biochemical recurrence. 12, 13 Radiation given for a biochemical failure, palpable or biopsy-proven local disease recurrence is considered salvage. Radiation administered when there is clear evidence of disease recurrence or persistence is also referred to as therapeutic EBRT, implying correctly that EBRT in the adjuvant setting may not always be therapeutic. Finally, radiation applied to men both with and without evidence of disease recurrence is called 'post-operative' radiation, a less precise term that describes the mixed cohort of men in a recently completed EORTC and Southwest Oncology Group (SWOG) trials (see below).
According to the American Society for Therapeutic Radiology and Oncology 1999 Consensus Panel, 'the highest dose of radiation therapy that can be given without morbidity is justifiable'.
14 The panel recommended the dose should be 64 Gy or slightly higher, with standard fractionation (1.8 or 2.0 Gy per fraction).
Adjuvant radiation therapy
The most frequently studied modality is adjuvant radiation therapy. A number of retrospective studies demonstrated that adjuvant radiation therapy improves progression-free survival (PFS) and local controls (Table 1) . [15] [16] [17] [18] [19] [20] [21] [22] In all cases, biochemical survival was improved with the use of adjuvant radiation therapy. However, no benefit was identified in studies that also examined either metastasis-free, overall or prostate cancer-specific survival. 16, 18, 19, 21, 23, 24 This is consistent with a treatment modality that helps control only locoregional disease.
There are four clinical scenarios that face the patient considering adjuvant EBRT. First, there is no residual cancer and EBRT is unnecessary. Second, there is residual cancer limited to the prostatic fossa and EBRT can provide long-term cure. Third, there is residual local prostate cancer as well as microscopic metastatic disease; local EBRT may treat the local problem but will have no impact on the systemic disease. Finally, the only residual disease is systemic and local EBRT is unnecessary. Only the second scenario provides a potential benefit to the patient.
In considering the results of various series of adjuvant EBRT compared with salvage EBRT, as listed in Table 2 , the 5-year actuarial biochemical disease-free rates following adjuvant EBRT are better than salvage EBRT. Those favoring adjuvant EBRT argue that these different outcomes reflect an increased efficacy of EBRT with smaller tumor burden, and the more timely elimination of prostate cancer cells are destined to become metastatic if left alone. 25, 26 In the face of limited morbidity, proponents believe that adjuvant EBRT is indicated.
On the other hand, some men who received adjuvant EBRT in these studies did not need it: they were cured by surgery alone, as described by the first clinical scenario above. Inclusion of this unknown subset makes the outcome data for adjuvant EBRT better than if only those with residual disease are included. What is the likely size of this subset? The recent data from the Mayo clinic indicate that 65% of men with a single-positive surgical margin and no other treatment remain biochemically/ clinically free from disease at 5 years; 62% men with two or more positive margins had no evidence of disease at 5 years. 27 Therefore, it is possible that a majority of men could receive adjuvant EBRT for a positive margin unnecessarily.
The EORTC has recently reported early results from a randomized prospective adjuvant EBRT trial. 28 After radical prostatectomy, 1005 patients with positive margins, extracapsular disease or seminal vesicle involvement were randomized to adjuvant EBRT (50-74 Gy to prostate bed) (n ¼ 502) vs no immediate treatment (n ¼ 503). Several important end points were improved in a statistically significant manner by adjuvant radiation therapy: 5-year biochemical PFS was improved from 53 to 74%, local PFS was improved from 85 to 95% and clinical PFS was improved from 78 to 85%. However, the more clinically meaningful end points were not improved. Five-year metastasis-free survival, prostate cancer-specific survival and overall survival were not effected by adjuvant EBRT. As the follow-up is relatively short, it is possible that a more robust end point will be reached in the future. 28 SWOG recently reported trial 8794, which also treated men with high-risk localized disease with adjuvant radiation therapy. With longer follow-up (10.6 years), Postsurgical options for high-risk prostate cancer AS Kibel and JB Nelson the results are very similar to the EORTC study described above: biochemical-free survival (median PSA relapse-free survival, 10.3 years for radiotherapy vs 3.1 years for observation, Po0.001) and disease recurrence (median recurrence-free survival, 13.8 years for radiotherapy vs 9.9 years for observation P ¼ 0.001) were both significantly reduced with radiotherapy. However, metastasis-free and overall survival were not improved (P ¼ 0.06 and 0.16), though the study approached statistical significance for both these end points. Complications such as rectal complications, urethral strictures and total urinary incontinence were more common with radiotherapy cohort in a statistically significant manner. 29 Both the EORTC and SWOG trials provide evidence that adjuvant radiation therapy clearly improves biochemical recurrence rates. This is very similar to the non-randomized data. It remains to be seen if salvage radiation therapy would provide similar responses and would spare many patients from unnecessary adjuvant radiation therapy and its associated side effects.
Salvage radiation therapy
A large retrospective analysis of salvage radiation therapy was reported by Stephenson 30 in 2004. A cohort of 501 men from five academic centers were treated in the salvage setting between 1987 and 2002. At a median follow-up of 45 months, 250 (50%) patients treated with salvage radiation had disease progression. The 4-year progression-free probability was 45% (95% confidence interval (CI) 40-50%). In multivariant analysis, significant predictors of progression included Gleason score 8-10, pre-radiation therapy PSA 42 ng/ml, negative surgical margins, PSA doubling time less than 10 months and seminal vesicle invasion. Although the pathologic and PSA criteria are not at all surprising, the worse outcome associated with a negative margin (generally considered a favorable pathologic factor) is, at first glance, paradoxical. The presence of a positive surgical margin increases the likelihood that there is residual prostate cancer in the prostatic fossa. On the other hand, the durable response of some patients (43%) with reportedly negative surgical emphasizes the deficiencies of pathological assessment of margin status. 
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Although the disease-free rates following radiotherapy in the salvage setting are less than 50% and, depending on the various risk factors, considerably less, it remains the only treatment following radical prostatectomy that still holds the promise of cure.
Systemic treatment
Until recently, the most active chemotherapeutic agent, mitoxantrone, ameliorated symptoms, but had little effect on survival. 31, 32 As a result, the treatment for hormone refractory disease revolved around improved hormone ablation, which provided a PSA response on average of 4 months, but no change in survival. [33] [34] [35] Recently, two randomized prospective trials, SWOG 9916 and TAX 327, demonstrated a survival advantage for chemotherapy. 36, 37 Whereas the survival benefit for docetaxel was fairly modest for 2-3 months, the success of these trials represents a paradigm shift in the treatment of prostate carcinoma. Systemic treatment works. The task now is to build on this initial success. One way is to introduce systemic treatment earlier in the disease process.
Neo-adjuvant systemic treatment
Neo-adjuvant hormone ablation has been the best studied. Interest in this approach has been spurred by success of hormone ablation in conjunction with EBRT. Bolla et al. 38 demonstrated an improved disease-free survival and overall survival with 3 years of hormone ablation. Many other studies have explored the synergy between EBRT and hormone ablation and found that it improves survival. [39] [40] [41] Neo-adjuvant hormone ablation has been well studied before radical prostatectomy. Five randomized trials have studied the utility of neo-adjuvant hormone therapy (Table 3) . Studies used a variety of ablation agents and treated patients for 3 months before radical prostatectomy. All the studies initially demonstrated a decrease in positive margin rates; however, the four studies that provided longer follow-up demonstrated no difference in biochemical-free survival. [42] [43] [44] [45] [46] Many studies included patients with low-risk disease and possibly could not benefit from a multimodality approach.
To address this issue, Klotz et al. 47 performed subset analysis on a subset of patients with Gleason 8-10 or PSA 420 ng/ml. They found that 3 months of neo-adjuvant hormone therapy was associated with a decrease in biochemical recurrence in patients with PSA420 ng/ml (53 vs 35%; P ¼ 0.015) and Gleason sum 8-10 (79 vs 63%; P ¼ 0.080).
A second criticism of these neo-adjuvant hormone ablation studies is that treatment was relatively short compared with the 3 years of androgen deprivation used in the Bolla trial. Gleave et al. 48 addressed this issue by randomizing 549 men to 3 months vs 8 months of deprivation. Again margin-positive rates decreased from 12 to 23% (P ¼ 0.01), but there was no difference in biochemical-free survival at 3 years.
Recent chemotherapeutic studies, which demonstrated improved response rates and lower toxicities in hormone refractory disease, 31, 32, 36, 37 have stimulated interest in treating high-risk local disease. Five trials using a neoadjuvant approach have been reported (Table 4) . [49] [50] [51] [52] [53] The primary end point of each was to achieve a P0; however, to date no trial has reported a single success. The trials that incorporated estramustine had complication rates of 12-34%. Given that estramustine causes hypercoagulability it is not surprising that thromboembolic complications were particularly high. Monotherapy with docetaxel was well tolerated in two trials. 50, 51 Dreicer et al. 51 and Febbo et al. 50 recently reported phase II trials of neo-adjuvant docetaxel. Overall, from both studies, 45 of 48 patients completed treatment. Dreicer et al. 51 found that 93% of the patients achieved an undetectable PSA postoperatively, and at 23 months 71% were diseasefree. Febbo et al. 50 found that at 27 months, 44% were disease-free. Approximately, 15% had grade 3 or 4 toxicity and one patient had a thromboembolic event. These phase II study results, along with the success of docetaxel in hormone refractory disease, has led to the implementation of an intergroup trial (CALGB 90203) randomizing patients to radical prostatectomy with or without neo-adjuvant hormone ablation and docetaxel.
Adjuvant systemic treatment
Androgen ablation is the best-studied option. Interest in this approach has been fostered by three prospective randomized trials examining early hormonal ablation.
Although all three studies demonstrate an advantage in Postsurgical options for high-risk prostate cancer AS Kibel and JB Nelson subpopulations, all have been shortcomings. [54] [55] [56] The Medical Research Council study randomized 934 patients with advanced localized disease or asymptomatic disease, to immediate vs delayed hormone ablation. The authors found a clear benefit to immediate treatment. While this study has been criticized because many patients died without receiving therapy, the key issue for evaluating the study in the context of adjuvant treatment is that the patients did not undergo potentially curative therapy. Therefore, extrapolation to high-risk surgical patients is not possible. 54 Messing et al. 55 randomized 98 men with positive lymph nodes at the time of radical prostatectomy to immediate hormone ablation vs ablation at the time of metastasis. At a median follow-up of 11.9 years, men assigned to immediate ablation had an improvement in overall survival (hazard ratio 1.84; 95% CI 1.01-3.35; P ¼ 0.04), prostate cancer-specific survival (4.09; 1.76-9.49; P ¼ 0.0004) and PFS (3.42; 1.96-5.98; Po0.0001). The inability of the trial to reach its accrual goals, the lower than expected survival in the control arm, the delivery of hormone therapy in the control arm at the time of metastasis and the fact that only nodepositive patients were studied has raised concerns as to whether this should be the standard of care for all high-risk patients.
Wirth et al. 56 studied high-dose bicalutamide in a worldwide study of over 8000 patients with a range of stages and treatments. They reported a small but statistically significant advantage with bicalutamide on PFS, but not overall survival. Although subset analysis appeared to demonstrate that the benefit was predominantly in patients with locally advanced disease, it is important to note that there was no benefit in the North American arm of the trial. This trial should be followed closely in the coming years but, currently, it is unknown if adjuvant bicalutamide is effective.
As majority of patients with high-risk pathology fail with distant disease, 57 it is clear that improved systemic therapy is needed. Currently, there are two important adjuvant trials. Although mitoxantrone did not demonstrate a survival advantage in hormone refractory disease, 31, 32 SWOG 9921 is designed to determine if earlier use of mitoxantrone, when tumor burden is lower, will improve survival. Docetaxel is a second systemic agent that has demonstrated superior efficacy to mitoxantrone in hormone refractory prostate carcinoma. 36, 37 A phase II study demonstrated that adjuvant docetaxel was well tolerated. Two patients had grade IV hyperglycemia. Grade III toxicities were hyperglycemia (7.7%), dyspnea (5.2%) and leukopenia (3.9%). Seven patients died; four from progressive disease, one from a sudden cardiac death, one from intra-abdominal bleeding and one from pneumonia. The later two deaths were possibly related to treatment. At median follow-up of 28 months (range 10.5-38.5), 46 of 76 evaluable patients (60.5%) progressed. The observed median PFS was 15.7 months (95% CI 12.8À25.1 months). The predicted median PFS for a matched population was 10 months. 58 As a result of the phase II data on tolerability and the phase III data on efficacy in hormone refractory disease, an international phase III trial is being implemented to test the adjuvant docetaxel in patients at high-risk for recurrence.
Conclusion
Patients with locally advanced prostate cancer are at increased risk of PSA failure, metastasis and death from systemic disease. The most common adjuvant treatment is EBRT. However, although recent data have demonstrated that adjuvant EBRT following RRP decreases biochemical and local progression, it does not change metastasis, disease-specific or overall survival. Many advocate salvage EBRT for PSA failure as a less toxic alternative. Neo-adjuvant hormonal therapy provides a clear survival advantage with EBRT but not with surgery. Adjuvant hormone therapy has demonstrated an improvement in disease-specific survival and overall Postsurgical options for high-risk prostate cancer AS Kibel and JB Nelson survival in node-positive patients, but it is unknown if that survival advantage translates to other high-risk groups. Lastly, chemotherapy has proven efficacy in hormone refractory prostate cancer with relatively low toxicity but remain to be proven as useful adjuvant therapy. On-going trials will help answer this important question.
